Table 5.

TEAEs occurring in ≥5% of patients in any group (safety ITT population).

	Recently diagnosed (≤3 years) (n = 233)	Chronic (>3 years) (n = 360)
	Number of patients (%)
Injection-site pain	30 (12.9)	43 (11.9)
Insomnia	23 (9.9)	28 (7.8)
Anxiety	15 (6.4)	25 (6.9)
Headache	14 (6.0)	19 (5.3)
Akathisia	13 (5.6)	15 (4.2)
Somnolence	12 (5.2)	14 (3.9)
Weight increased	12 (5.2)	7 (1.9)
Depression	12 (5.2)	6 (1.7)
Psychotic disorder	11 (4.7)	25 (6.9)

ITT: intent-to-treat; TEAEs: treatment-emergent adverse events.